Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation

Blood

Volumn 89, Issue 8, 1997, Pages 3055-3060

  Slattery, J T ^b   Clift, R A ^a   Buckner, C D ^b   Radich, J ^b   Storer, B ^b   Bensinger, W I ^b   Soll, E ^b   Anasetti, C ^b   Bowden, R ^b   Bryant, E ^b   Chauncey, T ^b   Deeg, H J ^b   Doney, K C ^b   Flowers, M ^b   Gooley, T ^b   Hansen, J A ^b   Martin, P J ^b   McDonald, G B ^b   Nash, R ^b   Petersdorf, E W ^b   Sanders, J E ^b   Schoch, G ^b   Stewart, P ^b   Storb, R ^b   Sullivan, K M ^b   Thomas, E D ^b   Witherspoon, R P ^b   Appelbaum, F R ^b   more..

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; FLUCONAZOLE; GANCICLOVIR;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER VENOOCCLUSIVE DISEASE; MALE; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENCE RISK;

EID: 0030902219     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.8.3055     Document Type: Article

References (33)

1. Clift RA, Buckner CD, Thomas ED, Doney K, Fefer A, Neiman PE, Singer J, Sanders J, Stewart P, Sullivan KM, Deeg J, Storb R: Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation. Lancet 2:621, 1982
2. Goldman JM, Baughan ASJ, McCarthy DM, Worsley AM, Hows JM, Gordon-Smith EC, Catovsky D, Batchelor JR, Goolden AWG, Galton DAG: Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia. Lancet 2:623, 1982
3. McGlave PB, Arthur DC, Kim TH, Ramsay NKC, Hurd DD, Kersey J: Successful allogeneic bone marrow transplantation for patients in the accelerated phase of chronic granulocytic leukaemia. Lancet 2:625, 1982
4. Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, Buckner CD, Cheever MA, Deeg HJ, Doney K, Flournoy N, Greenberg P, Hansen JA, Martin P, McGuffin R, Ramberg R, Sanders JE, Singer J, Stewart P, Storb R, Sullivan K, Weiden PL, Witherspoon R: Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104:155, 1986
5. Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AWG, Batchelor R, Hale G, Waldmann H, Reid CD, Hows J, Gordon-Smith E, Catovsky D, Galton DAG: Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 314:202, 1986
6. Clift RA, Appelbaum FR, Thomas ED: Treatment of chronic myeloid leukemia by marrow transplantation. Blood 82:1954, 1993 (review)
7. Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A, Masaoka T, McGlave PB, Messner H, O'Reilly RJ, Reiffers J, Rimm AA, Speck B, Veum-Stone JA, Wingard JR, Zwaan FE, Bortin MM: Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82:2235, 1993
8. Buckner CD, Clift RA: Timing of allogeneic marrow transplants for patients with chronic myeloid leukemia. Bone Marrow Transplant 15:S203, 1995
9. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, Deeg HJ, Doney KC, Fisher LD, Hansen JA, Martin P, McDonald GB, Sanders JE, Schoch G, Singer J, Storb R, Sullivan KM, Witherspoon RP, Appelbaum FR: Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84:2036, 1994
10. Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, Anasetti C, Bensinger WI, Fisher LD, Appelbaum FR, Hansen JA: Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16:31, 1995
11. Vassal G: Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: Rationale and pitfalls. Anticancer Res 14:2363, 1994 (review)
12. Demirer T, Buckner CD, Appelbaum FR, Lambert K, Bensinger WI, Clift R, Storb R, Slattery JT: Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant 17:341, 1996
13. Storb, R, Deeg HJ, White-head J, Appelbaum F, Beatty P, Bensinger W, Buekner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729, 1986
14. Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C, Appelbaum FR, Bowden R, Deeg HJ, Doney K, Martin PJ, Sullivan KM, Sanders J, Witherspoon RP: Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 80:1838, 1992
15. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED: Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825, 1995
16. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, Beatty PG, Doney K, McDonald GB, Sanders JE, Sullivan KM, Storb R, Thomas ED, Witherspoon RP, Lomen P, Hannigan J, Hansen JA: A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood 76:1464, 1990
17. Martin PJ, Schoch G, Fisher L, Byers V, Appelbaum FR, McDonald GB, Storb R, Hansen JA: A retrospective analysis of therapy for acute graft-versus-host disease: Secondary treatment. Blood 77:1821, 1991
18. Sullivan KM, Witherspoon RP, Storb R, Deeg HJ, Dahlberg S, Sanders JE, Appelbaum FR, Doney KC, Weiden P, Anasetti C, Loughran TP, Hill R, Shields A, Yee G, Shulman H, Nims J, Strom S, Thomas ED: Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-versus-host disease. Blood 72:555, 1988
19. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, Deeg HJ, Sanders JE, Doney KC, Appelbaum FR, McGuffin R, McDonald GB, Meyers J, Schubert MM, Gauvreau J, Shulman HM, Sale GE, Anasetti C, Loughran TP, Strom S, Nims J, Thomas ED: Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-versus-host disease: Prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 72:546, 1988
20. Hansen JA, Mickelson EM, Choo SY, Petersdorf EW, Anasetti C, Martin PJ, Thomas ED: Clinical bone marrow transplantation: Donor selection and recipient monitoring, in Rose NR, De Macario EC, Fahey JL, Friedman H, Penn GM (eds): Manual of Clinical Laboratory Immunology. Washington, DC, American Society of Microbiology, 1992, p 850
21. Petersdorf EW, Smith AG, Mickelson EM, Martin PJ, Hansen JA: Ten HLA-DR4 alleles defined by sequence polymorphisms within the DRB1 first domain. Immunogenetics 33:267, 1991
22. Mickelson E, Smith A, McKinney S, Anderson G, Hansen JA: A comparative study of HLA-DRB1 typing by standard serology and hybridization of non-radioactive sequence-specific oligonucletide probes to PCR-amplified DNA. Tissue Antigens 41:86, 1993
23. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED; Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562, 1988
24. Durnam DM, Anders KR, Fisher L, O'Quigley JO, Bryant EM, Thomas ED: Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay. Blood 74:2220, 1989
25. Scharf SI, Smith AG, Hansen JA, McFarland C, Erlich HA: Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood 85:1954, 1995
26. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W: A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86:3598, 1995
27. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118:173, 1993
28. Goodrich JM, Boeckh M, Bowden R: Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 19:287, 1994
29. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA: Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation - A randomized double-blind study. Blood 88:4063, 1996
30. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, Meyers JD, Bowden RA: Efficacy and safety of fluconazole for fungal infections after marrow transplant - A prospective, randomized, double-blind study. J Infect Dis 171:1545, 1995
31. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
32. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966
33. Pepe MS, Longton G, Pettinger M, Mori M, Fisher LD, Storb R: Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: Motivation for and description of new methods. Br J Haematol 83:602, 1993